SCHEDULE 1Modifications to the 2013 Regulations for pre-F2IP completion day cases
I11
The modifications of the 2013 Regulations referred to in regulation 16 are that those Regulations are to be read as if—
a
in regulation 2 (interpretation)—
i
in the definition of “resident patient”, for “the United Kingdom is” there were substituted “
immediately before F1IP completion day the United Kingdom was
”
;
ii
in the definition of “visiting patient”, for “a member State other than the United Kingdom is” there were substituted “
immediately before F1IP completion day a member State other than the United Kingdom was
”
;
b
in the heading to regulation 5 (national contact point: information about treatment in another member State), for “another member State” there were substituted “
a member State
”
;
c
in regulation 5—
i
for references to “other member States” there were substituted “
member States
”
;
ii
for the reference to “another member State” there were substituted “
a member State
”
;
d
regulation 5A (National Contact Point: information about prescriptions intended to be used in another member State) were omitted;
F3e
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
f
regulation 7 (National Contact Point: duty to consult) were omitted;
g
in regulation 12—
i
in paragraph (2) for “P is” there were substituted “
immediately before F1IP completion day P was
”
;
ii
in paragraph (2)(a), for “is resident” there were substituted “
was resident
”
;
iii
in paragraph (2)(b), for “is the competent member State” there were substituted “
was the competent member State
”
;
iv
in paragraph (4)(b) at the end there were inserted “as it had effect immediately before F1IP completion day”;
h
the schedule (elements that must be included in prescriptions intended to be used in another member State) were omitted.
Words in Sch. 1 heading substituted (31.12.2020 immediately before IP completion day) by The Reciprocal and Cross-Border Healthcare (Amendment etc.) (EU Exit) Regulations 2020 (S.I. 2020/1348), regs. 1, 15(a)